Treatment of PMSA expressing cancers

US10980901B2 · kind B2 · utility

Assignees

• THE EUROPEAN ATOMIC ENERGY COMMUNITY (EURATOM), REPRESENTED BY THE EUROPEAN COMMISSION · BE
• Universität Heidelberg · DE

Inventors

• Alfred Morgenstern · Karlsruhe, DE
• Frank BRUCHERTSEIFER · Blankenloch, DE
• Christos Apostolidis · Heidelberg, DE
• Uwe Haberkorn · Schwetzingen, DE
• Frederik GIESEL · Heidelberg, DE
• Clemens KRATOCHWIL · Hirschberg, DE

Key dates

• Filing date: Dec 15, 2016
• Grant date: Apr 20, 2021
• Expiry date: Dec 15, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.